Cesca Therapeutics Inc (KOOL) - NASDAQ
  • Thu, May 12, 4:43 PM
    • Cesca Therapeutics (NASDAQ:KOOL): FQ3 Net loss of $2.7M.
    • Revenue of $2.8M (-30.7% Y/Y) misses by $1.88M.
    • Press Release
    | Thu, May 12, 4:43 PM
  • Tue, Feb. 16, 4:08 PM
    • Cesca Therapeutics (NASDAQ:KOOL): FQ2 EPS of -$0.02 beats by $0.05.
    • Revenue of $3.3M (-28.9% Y/Y) misses by $1.02M.
    • Press Release
    | Tue, Feb. 16, 4:08 PM
  • Nov. 16, 2015, 4:08 PM
    • Cesca Therapeutics (NASDAQ:KOOL): FQ1 EPS of -$0.08 misses by $0.02.
    • Revenue of $2.82M (-23.0% Y/Y) misses by $0.89M.
    | Nov. 16, 2015, 4:08 PM
  • Sep. 18, 2015, 6:55 AM
    • Cesca Therapeutics (KOOL -10.4%) FQ4 results: Revenues: $3.7M (-2.6%); COGS: $2.8M (+3.7%); R&D Expense: $1.2M (+9.1%); SG&A: $2.1M (-38.2%); Net Loss: ($2.4M) (+17.2%); Loss Per Share: ($0.06) (+25.0%).
    • FY2015 results: Revenues: $16M (+0.3%); COGS: $11.3M (+11.9%); R&D Expense: $5.9M (+68.6%); SG&A: $13.7M (+19.1%); Net Loss: ($14.9M) (-73.3%); Loss Per Share: ($0.37) (-2.8%); Quick Assets: $3.4M (-77.0%).
    • No guidance given.
    | Sep. 18, 2015, 6:55 AM
  • Sep. 17, 2015, 4:08 PM
    • Cesca Therapeutics (NASDAQ:KOOL): FQ4 EPS of -$0.06 beats by $0.05.
    • Revenue of $3.7M (-3.6% Y/Y) misses by $0.58M.
    | Sep. 17, 2015, 4:08 PM
  • Jun. 24, 2015, 6:47 AM
    • Cesca Therapeutics (KOOL +2.2%) FQ3 results: Revenues: $4M (+0.1%); COGS: $2.9M (+16.0%); R&D Expense: $1.7M (+112.5%); SG&A: $4.3M (+65.4%); Net Loss: ($4.8M) (-152.6%); Loss Per Share: ($0.12) (-71.4%); Quick Assets: $4.8M (-67.6%); CF Ops: ($9.3M) (-52.5%).
    • No guidance given.
    | Jun. 24, 2015, 6:47 AM
  • Jun. 23, 2015, 4:09 PM
    • Cesca Therapeutics (NASDAQ:KOOL): FQ3 EPS of -$0.12 misses by $0.02.
    • Revenue of $4.04M (flat Y/Y) misses by $0.54M.
    | Jun. 23, 2015, 4:09 PM | 1 Comment
  • Feb. 13, 2015, 10:24 AM
    • Cesca Therapeutics (KOOL -5.9%) FQ2 results: Revenues: $4.6M (+2.2%); COGS: $3.1M (+14.8%); Operating Expense: $5.9M (+73.5%); Net Loss: ($4.4M) (-175.0%); Loss Per Share: ($0.11) (-10.0%); Quick Assets: $8.4M (-43.2%); CF Ops: ($5.9M) (-37.2%).
    • No guidance given.
    | Feb. 13, 2015, 10:24 AM | 1 Comment
  • Feb. 12, 2015, 4:11 PM
    • Cesca Therapeutics (NASDAQ:KOOL): FQ2 EPS of -$0.11 misses by $0.03.
    • Revenue of $4.64M (+4.3% Y/Y) beats by $0.56M.
    | Feb. 12, 2015, 4:11 PM
  • Nov. 13, 2014, 4:16 PM
    • Cesca Therapeutics (NASDAQ:KOOL): FQ1 EPS of -$0.08 misses by $0.01.
    • Revenue of $3.7M (+2.8% Y/Y) beats by $0.9M.
    | Nov. 13, 2014, 4:16 PM
  • Nov. 12, 2014, 9:29 AM
    • Cesca Therapeutics (NASDAQ:KOOL) will report fiscal Q1 results tomorrow, November 13, after the close. The conference call will begin at 2:00 pm PT/5:00 pm ET.
    • Consensus view is a loss of ($0.07) per share on revenues of $2.8M.
    | Nov. 12, 2014, 9:29 AM
  • Sep. 29, 2014, 10:28 AM
    • Cesca Therapeutics (KOOL -3.3%) financial results:
    • Fiscal Q4: Revenues: $3.8M (-7.5%); Gross Profit: $1.2M (+7.4%); Operating Expenses: $4.4M (+28.3%); Net Loss: ($2.9M) (-20.0%); Loss Per Share: ($0.08) (+42.9%); Quick Assets: $14.8M (+115.2%).
    • Fiscal 2014: Revenues: $16.0M (-11.0%); Gross Profit: $5.9M (-7.5%); Operating Expenses: $14.9M (+58.3%); Net Loss: ($8.6M) (-179.7%); Loss Per Share: ($0.36) (-89.5%); Cash Burn: ($7.8M) (-154.3%).
    • No financial guidance given.
    | Sep. 29, 2014, 10:28 AM
  • Sep. 29, 2014, 6:59 AM
    • Cesca Therapeutics (NASDAQ:KOOL): FQ4 EPS of -$0.08 misses by $0.02.
    • Revenue of $3.83M (-7.7% Y/Y) misses by $0.44M.
    | Sep. 29, 2014, 6:59 AM
  • May 15, 2014, 4:53 PM
    • Cesca Therapeutics (KOOL): FQ3 EPS of -$0.07.
    • Revenue of $4.04M.
    • Shares -2.01% AH.
    | May 15, 2014, 4:53 PM
  • Aug. 29, 2013, 6:02 PM
    • ThermoGenesis (KOOL) posts an FQ4 loss of $0.14 per share on revenues of $4.1M. This compares to a loss per share of $0.04 on revenues of $4.5M in the same quarter a year ago.
    • No analyst estimates were available for comparison. (PR)
    • Shares +1.7% AH.
    | Aug. 29, 2013, 6:02 PM
Company Description
Cesca Therapeutics, Inc. is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. It is engaged in developing and manufacturing automated blood and bone marrow processing systems and companion disposable products that... More
Sector: Healthcare
Industry: Medical Appliances & Equipment
Country: United States